EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimized procurement of cancer-reactive T-cell receptors from clinical samples

Marine E Caillaud, Cristina Rius, Théo Morin, Li Rong Tan, Hannah L Thomas, Amber Rogers, Joshua Hick, Morten Nielsen, Md Samiul Hasan, Inge Marie Svane, Barbara Szomolay, Andrew K Sewell iD und 1 weitere

Immunotherapy Advances · 31.12.2025 · 6 (1)

DOI: 10.1093/immadv/ltag009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 22.06.2026. Verfasst von Marine E Caillaud und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Wellcome Investigator, Tom Walker PhD studentship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T-cell receptors can sense cancer-associated changes in cellular proteins, lipids, metabolites, and stress pathways, enabling immune-mediated tumour elimination in some patients. These receptors underpin T-cell receptor-based immunotherapies, yet their isolation from clinical samples remains challenging due to labour-intensive workflows, dependence on prior antigen knowledge, and loss of cell viability. We developed an optimized flow cytometry-based assay, termed the T107 assay, to isolate viable cancer-reactive T-cells directly from clinical samples. Following short-term exposure to cancer cells, responding T-cells are identified by simultaneous surface detection of tumour necrosis factor and the degranulation marker CD107a, enabling recovery of live antigen-reactive cells for downstream analysis. The T107 assay enabled rapid identification of cancer-reactive T-cells from tumour-infiltrating lymphocyte products derived from melanoma and sarcoma patients. The assay supported phenotypic and functional characterization of αβ and γδ T-cell receptor populations, including CD4+ and CD8+ subsets, responding to both patient-specific and shared cancer antigens. Isolation of viable responding cells enabled high-resolution receptor sequencing, generation of functional T-cell clones, determination of antigen specificity and major histocompatibility complex restriction or independence. Paired receptors were engineered into primary T-cells to generate T-cell receptor-engineered products capable of recognizing multiple cancer types. The T107 assay provides a rapid and robust method for antigen-agnostic procurement of viable cancer-reactive T-cells and their receptors from clinical material. This approach removes key bottlenecks in T-cell receptor discovery and is expected to accelerate development of T-cell receptor-based immunotherapies across a broad range of cancers.

Schlagwörter

Stichwörter der Autor:innen

T-cell receptor sequencingcancerflow cytometryimmunotherapyviable T-cells

Autor:innen und Institutionen

  • Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, United Kingdom.
  • Centre for Cancer Immune Therapy, Herlev Hospital, Copenhagen University, Copenhagen, Denmark.
  • Systems Immunity Research Institute, Cardiff University Cardiff, Wales, United Kingdom.
  • Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 8600811, Japan.

ORCID-Profile: Andrew K Sewell

Förderung

  • Wellcome Trust
  • Wellcome Investigator
  • Tom Walker PhD studentship
  • Acute Myeloid Leukaemia Research
  • Cancer Research Wales
  • Tenovus Cancer Care

Zitieren

APA

Caillaud, M. E., Rius, C., Morin, T., Tan, L. R., Thomas, H. L., Rogers, A., Hick, J., Nielsen, M., Hasan, M. S., Svane, I. M., Szomolay, B., Sewell, A. K., & Dolton, G. (2025). Optimized procurement of cancer-reactive T-cell receptors from clinical samples. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag009

Vancouver

Caillaud ME, Rius C, Morin T, Tan LR, Thomas HL, Rogers A, et al. Optimized procurement of cancer-reactive T-cell receptors from clinical samples. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag009

BibTeX
@article{Caillaud2025,
  author = {Caillaud, Marine E and Rius, Cristina and Morin, Théo and Tan, Li Rong and Thomas, Hannah L and Rogers, Amber and Hick, Joshua and Nielsen, Morten and Hasan, Md Samiul and Svane, Inge Marie and Szomolay, Barbara and Sewell, Andrew K and Dolton, Garry},
  title = {Optimized procurement of cancer-reactive T-cell receptors from clinical samples},
  journal = {Immunotherapy Advances},
  year = {2025},
  volume = {6},
  number = {1},
  doi = {10.1093/immadv/ltag009}
}
Kostenlos starten →